Nice drug if you can get it. Can’t get it if you try?* On the current scarcity of semaglutide (et alia).

---

Decarbonizing the Pharma Supply Chain

---

Drugs and APIs shortage put EU patients at risk

---

Enhancing patient outcomes: Strategies for a post-pandemic Life Sciences sector

---

Navigating a complex life sciences environment in 2023

---

Integrating Quality into production to drive cost-effective innovation

---

Particle Engineering to Optimise the Performance of Inhaled Therapeutics

---

Sourcing responsibly, can it be done?

---

The impact of the ukraine war on patients and medical innovation

---

Promoting wastewater treatment practices within the pharmaceutical supply chain to help revitalize the Musi River

---

Global campaigns towards local manufacture of anti-HIV/AIDS drugs in continuous flow systems

---

Around the Block(chain) – applications in pharma

---

Safety at the base of the choice of SIT (specific immunotherapy)

---

EFPIA and Vaccines Europe position on the European Health Emergency preparedness and Response Authority (HERA)

---

Pharma 4.0 manufacturing optimization using eData

---

Supporting human rights within the pharmaceutical supply chain

---

A new window of opportunity for brazilian API market

---

Local drug manufacturing in Africa: lessons learned from the COVID-19 Pandemic

---

Environmental sustainability in pharma – A view on Pharma’s progress towards positive impact

---

New Intellectual Property Risk Assessment Program for External Suppliers of Innovative Biopharmaceutical Medicines Part 2 – Execution Phase

---

Resilience of Pharma Supply Chains and the Impact of Covid-19 Pandemic

---

New Intellectual Property Risk Assessment Program for External Suppliers of Innovative Biopharmaceutical Medicines. Part 1 – Preparation Phase

---

Panel Discussion on: – Pharma Supply Chain – Finished Dosage Forms & Personalised Medicines

---

Transforming the Big Pharma People-Purpose System (PPS) with Joined Up Thinking (JUT)

---

Pharma 4.0 supply chain: security and data integrity for advanced therapies

---

Blockchain and the pharmaceutical industry

---

How whole systems thinking could transform the pharma value chain

---

Challenges and advances in cleaning ultrafiltration membranes used in bioprocessing

---

Extractables & leachables evaluation of single-use systems for biopharmaceuticals, moving toward new industrial standards – Part 2*

---